Literature DB >> 15504857

Potential for interactions between caspofungin and nelfinavir or rifampin.

Julie A Stone1, Elizabeth M Migoya, Lisa Hickey, Gregory A Winchell, Paul J Deutsch, Kalyan Ghosh, Amanda Freeman, Sheng Bi, Rajesh Desai, Stacy C Dilzer, Kenneth C Lasseter, Walter K Kraft, Howard Greenberg, Scott A Waldman.   

Abstract

The potential for interactions between caspofungin and nelfinavir or rifampin was evaluated in two parallel-panel studies. In study A, healthy subjects received a 14-day course of caspofungin alone (50 mg administered intravenously [IV] once daily) (n = 10) or with nelfinavir (1,250 mg administered orally twice daily) (n = 9) or rifampin (600 mg administered orally once daily) (n = 10). In study B, 14 subjects received a 28-day course of rifampin (600 mg administered orally once daily), with caspofungin (50 mg administered IV once daily) coadministered on the last 14 days, and 12 subjects received a 14-day course of caspofungin alone (50 mg administered IV once daily). The coadministration/administration alone geometric mean ratio for the caspofungin area under the time-concentration profile calculated for the 24-h period following dosing [AUC(0-24)] was as follows (values in parentheses are 90% confidence intervals [CIs]): 1.08 (0.93-1.26) for nelfinavir, 1.12 (0.97-1.30) for rifampin (study A), and 1.01 (0.91-1.11) for rifampin (study B). The shape of the caspofungin plasma profile was altered by rifampin, resulting in a 14 to 31% reduction in the trough concentration at 24 h after dosing (C(24h)), consistent with a net induction effect at steady state. Both the AUC and the C(24h) were elevated in the initial days of rifampin coadministration in study A (61 and 170% elevations, respectively, on day 1) but not in study B, consistent with transient net inhibition prior to full induction. The coadministration/administration alone geometric mean ratio for the rifampin AUC(0-24) on day 14 was 1.07 (90% CI, 0.83-1.38). Nelfinavir does not meaningfully alter caspofungin pharmacokinetics. Rifampin both inhibits and induces caspofungin disposition, resulting in a reduced C(24h) at steady state. An increase in the caspofungin dose to 70 mg, administered daily, should be considered when the drug is coadministered with rifampin.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15504857      PMCID: PMC525392          DOI: 10.1128/AAC.48.11.4306-4314.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species.

Authors:  J A Vazquez; M Lynch; D Boikov; J D Sobel
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

2.  Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans.

Authors:  T V Krishnarao; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

3.  In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).

Authors:  K Bartizal; C J Gill; G K Abruzzo; A M Flattery; L Kong; P M Scott; J G Smith; C E Leighton; A Bouffard; J F Dropinski; J Balkovec
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

4.  Synthesis and antifungal activity of novel cationic pneumocandin B(o) derivatives.

Authors:  F A Bouffard; R A Zambias; J F Dropinski; J M Balkovec; M L Hammond; G K Abruzzo; K F Bartizal; J A Marrinan; M B Kurtz; D C McFadden
Journal:  J Med Chem       Date:  1994-01-21       Impact factor: 7.446

5.  Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1.

Authors:  J E van Montfoort; B Stieger; D K Meijer; H J Weinmann; P J Meier; K E Fattinger
Journal:  J Pharmacol Exp Ther       Date:  1999-07       Impact factor: 4.030

6.  The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.

Authors:  B Greiner; M Eichelbaum; P Fritz; H P Kreichgauer; O von Richter; J Zundler; H K Kroemer
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

Review 7.  Safety and tolerability of caspofungin acetate in the treatment of fungal infections.

Authors:  C A Sable; B-Y T Nguyen; J A Chodakewitz; M J DiNubile
Journal:  Transpl Infect Dis       Date:  2002-03       Impact factor: 2.228

8.  Comparison of caspofungin and amphotericin B for invasive candidiasis.

Authors:  Jorge Mora-Duarte; Robert Betts; Coleman Rotstein; Arnaldo Lopes Colombo; Luis Thompson-Moya; Juanita Smietana; Robert Lupinacci; Carole Sable; Nicholas Kartsonis; John Perfect
Journal:  N Engl J Med       Date:  2002-12-19       Impact factor: 91.245

9.  The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro.

Authors:  J C Bowman; P Scott Hicks; M B Kurtz; H Rosen; D M Schmatz; P A Liberator; C M Douglas
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

10.  Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma.

Authors:  Julie A Stone; Xin Xu; Gregory A Winchell; Paul J Deutsch; Paul G Pearson; Elizabeth M Migoya; Goutam C Mistry; Liwen Xi; Alisha Miller; Punam Sandhu; Romi Singh; Florencia deLuna; Stacy C Dilzer; Kenneth C Lasseter
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

View more
  18 in total

Review 1.  Human pharmacogenomic variations and their implications for antifungal efficacy.

Authors:  Joseph Meletiadis; Stephen Chanock; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

Review 2.  Echinocandin antifungal drugs in fungal infections: a comparison.

Authors:  Sharon C-A Chen; Monica A Slavin; Tania C Sorrell
Journal:  Drugs       Date:  2011-01-01       Impact factor: 9.546

3.  Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients.

Authors:  Gudrun Würthwein; Charlotte Young; Claudia Lanvers-Kaminsky; Georg Hempel; Mirjam N Trame; Rainer Schwerdtfeger; Helmut Ostermann; Werner J Heinz; Oliver A Cornely; Hedwig Kolve; Joachim Boos; Gerda Silling; Andreas H Groll
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

Review 4.  Caspofungin: a review of its use in the treatment of fungal infections.

Authors:  Paul L McCormack; Caroline M Perry
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients.

Authors:  Chi-Chung Li; Peng Sun; Yingwen Dong; Sheng Bi; Rajesh Desai; Marissa Fallon Dockendorf; Nicholas A Kartsonis; Angela L Ngai; Susan Bradshaw; Julie A Stone
Journal:  Antimicrob Agents Chemother       Date:  2011-02-07       Impact factor: 5.191

Review 6.  Nelfinavir: a review of its use in the management of HIV infection.

Authors:  Caroline M Perry; James E Frampton; Paul L McCormack; M Asif A Siddiqui; Risto S Cvetković
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Antifungal agents in current pediatric practice.

Authors:  Cecinati Valerio; Teresa Perillo; Letizia Brescia; Fabio Giovanni Russo
Journal:  Curr Infect Dis Rep       Date:  2013-06       Impact factor: 3.725

8.  Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis.

Authors:  Gudrun Würthwein; Oliver A Cornely; Mirjam N Trame; Janne J Vehreschild; Maria J G T Vehreschild; Fedja Farowski; Carsten Müller; Joachim Boos; Georg Hempel; Michael Hallek; Andreas H Groll
Journal:  Antimicrob Agents Chemother       Date:  2013-01-18       Impact factor: 5.191

Review 9.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

10.  In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin.

Authors:  Bharat D Damle; James A Dowell; Robert L Walsky; Gregory L Weber; Martin Stogniew; Philip B Inskeep
Journal:  Antimicrob Agents Chemother       Date:  2008-11-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.